维普中文期刊产品整合服务
9篇 您的检索式:作者名="Joyce JS"
    题名 作者 年代 出处 被引量
1The L1 major cap- sid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes 显示文摘Joyce JG Tung JS Przysiecki CT 1999J Biol chem1999,274,9:1
2Alexithymia as a predictor of residual symptoms in depressed patients who respond to short - term psychotherapy显示文摘Ogrodniczuk JS Piper WE Joyce AS 2004Am J Psychother2004,58,:1
3Mutation of RET codon 768 is associated with the FMTC phenotype显示文摘BOCCIA LM GREEN JS JOYCE C 1997Clin Genet1997,51,:1
4Alexithymia as a predictor of residual symptoms in depressed patients who respond to short-term psychotherapy显示文摘Ogrodniczuk JS Piper WE Joyce AS 2004Am J Psychother2004,58,2:1
5Self-hypnotic relaxation during interventional radiological procedures:effects on pain perception and intravenous drug use显示文摘Lang EV Joyce JS Lee KK et a| 1996Int J Clin Exp Hypn1996,44,:1
6新型双汽源联合循环发电技术显示文摘新型双汽源联合循环发电技术德国西门子股份公司能源部JohnS.JoyceJuergenNiedersteberg在完全补燃型联合循环发电系统中,燃气轮机的排气在锅炉炉膛内做为劣质预热空气使普通煤或褐煤燃烧并产生蒸汽,供给蒸汽轮机。在新型的双汽源联合循...Joyc,JS 苏仪 1995中国电力1995,28,8:1
7Slrtwhu'e-based design of a fusion glycoprolein vaccine for respiratory syncylial virus 显示文摘McLellan JS Chcn M Joyce MG 2013Science2013,342,6158:1
8Human embryonic germ cell derivatives express a broad range of developmentally distinct markers and proliferate extensively in vitro显示文摘Michael JS Joyce A John WL 2001Proc Natl Acad Sci USA2001,98,1:1
9Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies显示文摘Objective:Chemotherapy-induced nausea and vomiting(CINV)are common with doxorubicin-cyclophosphamide(AC)chemotherapy.Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist(NK1 RA),5-hydroxytryptamine type-3 receptor antagonist(5 HT3 RA),corticosteroid,and dopamine antagonists.This post-hoc analysis compared results of 3 prospective antiemetic studies conducted among Chinese breast cancer patients who received(neo)adjuvant AC,in order to identify optimal antiemetic prophylaxis.Methods:A total of 304 patients were included:Group 1,ondansetron/dexamethasone(D1);Group 2,aprepitant/ondansetron/dexamethasone(D1);Group 3,aprepitant/ondansetron/dexamethasone(D1–3);Group 4,aprepitant/ondansetron/dexamethasone(D1–3)/olanzapine;and Group 5,netupitant/palonosetron/dexamethasone(D1–3).Antiemetic efficacies of Groups 3,4,and 5 during cycle 1 of AC were individually compared with Group 1.In addition,emesis outcomes of patients in Groups 3 and 5,and those of Groups 2 and 3,were compared.Results:When comparing efficacies of a historical doublet(5 HT3 RA/dexamethasone)with triplet antiemetic regimens(NK1 RA/5 HT3 RA/dexamethasone)with/without olanzapine,complete response(CR)percentages and quality of life(QOL)in overall phase of cycle 1 AC were compared between Group 1 and the other groups:Group 1 vs.3,41.9%vs.38.3%(P=0.6849);Group 1 vs.4,41.9%vs.65.0%(P=0.0107);and Group 1 vs.5,41.9%vs.60.0%(P=0.0460).Groups 4 and 5 achieved a better QOL.When comparing netupitant-based(Group 3)with aprepitant-based(Group 5)triplet antiemetics,CR percentages were 38.3%vs.60.0%,respectively(P=0.0176);Group 5 achieved a better QOL.When comparing 1 day(Group 2)vs.3 day(Group 3)dexamethasone,CR percentages were 46.8%and 38.3%,respectively(P=0.3459);Group 3 had a worse QOL.Conclusions:Aprepitant-containing triplets were non-superior to doublet antiemetics.Netupitant-containing triplets and adding olanzapine to aprepitant-containing triplets were superior to doublets.Netupitant/palonosetron/dexamethasone was superior to aprepitant/ondansetron/dexamethasone.Protracted administration of dexamethasone provided limited additional benefit.Winnie Yeo Leung Li Thomas KH Lau Kwai T Lai Vicky,TC Chan Kwan H Wong Christopher CH Yip Elizabeth Pang Maggie Cheung Vivian Chan Carol CH Kwok Joyce JS Suen Frankie KF Mo 2021Cancer Biology & Medicine2021,18,3:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费